Peapod Lane Capital LLC Acquires Shares of 396,221 Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Peapod Lane Capital LLC acquired a new stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 396,221 shares of the company's stock, valued at approximately $765,000. Peapod Lane Capital LLC owned about 0.92% of Kyverna Therapeutics at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of KYTX. Gilead Sciences Inc. purchased a new position in Kyverna Therapeutics in the fourth quarter valued at approximately $15,432,000. Jacobs Levy Equity Management Inc. raised its holdings in Kyverna Therapeutics by 2,225.0% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 461,959 shares of the company's stock valued at $1,728,000 after acquiring an additional 442,090 shares during the period. Integral Health Asset Management LLC raised its holdings in Kyverna Therapeutics by 75.0% during the 4th quarter. Integral Health Asset Management LLC now owns 350,000 shares of the company's stock valued at $1,309,000 after acquiring an additional 150,000 shares during the period. Geode Capital Management LLC raised its holdings in Kyverna Therapeutics by 21.7% during the 4th quarter. Geode Capital Management LLC now owns 539,682 shares of the company's stock valued at $2,019,000 after acquiring an additional 96,370 shares during the period. Finally, Bridgeway Capital Management LLC bought a new stake in Kyverna Therapeutics during the 4th quarter valued at $299,000. Hedge funds and other institutional investors own 18.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on KYTX. Morgan Stanley lowered their target price on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an "overweight" rating on the stock in a report on Tuesday, April 1st. HC Wainwright raised shares of Kyverna Therapeutics from a "neutral" rating to a "buy" rating and boosted their target price for the company from $4.00 to $5.00 in a report on Tuesday, May 27th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $18.50.

Kyverna Therapeutics Trading Up 14.8%

Shares of Kyverna Therapeutics stock traded up $0.46 during trading on Thursday, hitting $3.57. The stock had a trading volume of 895,448 shares, compared to its average volume of 386,557. The firm has a market cap of $154.29 million, a price-to-earnings ratio of -1.06 and a beta of 2.95. Kyverna Therapeutics, Inc. has a 12 month low of $1.78 and a 12 month high of $11.40. The business's 50-day moving average is $2.72 and its 200 day moving average is $2.78.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.21) by $0.18. As a group, equities analysts expect that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.